심부전과 과다호산구증가증으로 내원한 PDGFRB 유전변이가 동반된 골수성 종양
Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRB presenting as congestive heart failure and hypereosinophilia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including helminthic infections, adverse drug reactions, and allergic diseases. Primary/clonal bone marrow disease, including genetic mutations in platelet driven growth factor receptor alpha (PDGFRA), platelet driven growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor 1 (FGFR1) could be its causes. Although corticosteroids are the mainstay of therapy in confirmed HES, imatinib is considered a definitive treatment for HES with these mutations. However, there have been few reports about HES with these genetic mutations in Korea. Here, we report a patient who presented with sudden onset of congestive heart failure and hypereosinophilia, proved to have PDGFRB rearrangement, and was controlled successfully with imatinib after left ventricle thrombectomy.
Abstract
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including helminthic infections, adverse drug reactions, and allergic diseases. Primary/clonal bone marrow disease, including genetic mutations in platelet driven growth factor receptor alpha (PDGFRA), platelet driven growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor 1 (FGFR1) could be its causes. Although corticosteroids are the mainstay of therapy in confirmed HES, imatinib is considered a definitive treatment for HES with these mutations. However, there have been few reports about HES with these genetic mutations in Korea. Here, we report a patient who presented with sudden onset of congestive heart failure and hypereosinophilia, proved to have PDGFRB rearrangement, and was controlled successfully with imatinib after left ventricle thrombectomy.
참고문헌 (20)
- Haferlach T, "The diagnosis of BCR", ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers, 2008, pp.87, 1~10
- 김태희, "Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement", Blood Research, 51(3), pp.204~206 (2016), 대한혈액학회
- Kim M, "A case of chronic myelomonocytic leukemia with severe eosinophilia having t(5;12)(q31;p13) with t(1;7)(q10;p10)", Acta Haematol, 114, pp.104~107 (2005)
- 장상언, "호산구증가증과 PDGFRB 유전자 재배열을 보인 골수종양 1예", 대한내과학회지, 78(3), pp.386~390 (2010), 대한내과학회
- Hee-Jin Kim, "Chronic eosinophilic leukemia with a FIP1L1-PDGFRA rearrangement: Two case reports and a review of Korean cases", Blood Research, 50(1), pp.58~61 (2015), 대한혈액학회
- Keene P, "Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association", Br J Haematol, 67, pp.25~31 (1987)
- Golub TR, "Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation", Cell, 77, pp.307~316 (1994)
- Bain BJ, "Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome", Immunol Allergy Clin North Am, 27, pp.377~388 (2007)
- Walz C, "Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene", Haematologica, 92, pp.163~169 (2007)
- Wittman B, "A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate", Leuk Res, 28(Suppl 1), pp.S65~S69 (2004)
- Cools J, "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome", N Engl J Med, 348, pp.1201~1214 (2003)
- David M, "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders", Blood, 109, pp.61~64 (2007)
- Jovanovic JV, "Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia", Blood, 109, pp.4635~4640 (2007)
- Klion AD, "Relapse following discontinuation of imatinib mesylate therapy for FIP1L1", PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing, 2007, pp.110, 3552~3556
- Ogbogu PU, "Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy", J Allergy Clin Immunol, 124, pp.1319~1325 (2009)
- Weller PF, "The idiopathic hypereosinophilic syndrome", Blood, 83, pp.2759~2779 (1994)
- Pitini V, "Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes", Blood, 102, pp.3456~3457 (2003)
- Chusid MJ, "The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature", Medicine, 54, pp.1~27 (1975)
- Lefebvre C, "Prognostic factors of hypereosinophilic syndrome. Study of 40 cases", Ann Med Interne, 140, pp.253~257 (1989)
- Podjasek JC, "Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature", Leuk Res, 37, pp.392~395 (2013)